UNI-BIO SCIENCE GROUP (00690) announced that it has formally signed a tripartite strategic cooperation agreement in Wenzhou, Zhejiang Province with the Wenzhou Medical University National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations (WMU National Engineering Research Center) and the People's Government of Wenzhou's Ouhai District. The parties also discussed plans for the subsequent co-establishment of a "UNI-BIO - WMU Translational Medicine Joint Innovation Laboratory" (Joint Laboratory). This collaboration is designed to strengthen the Group's R&D pipeline in the fields of dermatology, ophthalmology, and metabolic diseases, while accelerating the implementation of its strategic initiatives. Under the agreement, the three parties will leverage their respective strengths in scientific research, industry, and policy to engage in comprehensive, chain-wide collaborative efforts—spanning from basic research and clinical translation to industrial commercialization—centered on the application of growth factor drugs in regenerative medicine. They intend to conduct in-depth exploration of the synergistic mechanisms of Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF) in areas such as regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, aiming to develop novel compound formulations and drug delivery systems for conditions including endocrine diseases like non-alcoholic steatohepatitis (NASH), respiratory diseases such as asthma, and bone tissue repair. These disease areas affect a vast global patient population, yet significant unmet needs for innovative therapies remain in clinical practice. Through this partnership and the future establishment of the Joint Laboratory, there is potential to address treatment gaps in several specialized indications, thereby unlocking substantial clinical and commercial value in the broad chronic disease market. The WMU National Engineering Research Center is an independent institutional legal entity established by Wenzhou Medical University based on the national-level scientific research platform. Under the leadership of Academician Li Xiaokun of the Chinese Academy of Engineering, it has long been deeply involved in basic research and new drug creation in the field of cell growth factor drugs, holding a globally leading position. The People's Government of Wenzhou's Ouhai District is a key promoter and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core industrial platform, the "China Gene Valley," provides comprehensive spatial support and specialized policy backing for the cooperative projects, covering everything from R&D and pilot-scale testing to industrialization. This collaboration is expected to enhance the Group's R&D efficiency and success rate in the field of innovative biologics, shorten product development cycles, and strengthen its comprehensive competitiveness in the specialized EGF/FGF segment. Furthermore, the cooperation is expected to facilitate the expansion of applications for the Group's existing products (including GenEpid® and GenEShu®) into more clinical scenarios. Additionally, the Board of Directors believes this partnership is a key initiative for the Group to deepen "government-university-enterprise" collaboration and integrate into a national-level innovation platform. It is anticipated to significantly accelerate the R&D and translation of cutting-edge innovation pipelines, further consolidating the Group's long-term competitiveness in regenerative medicine and delivering sustained value to shareholders.